Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE010 (ESP) (Dr. Silva)
· consented 2022-09-24
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-29 (study day 49); relationship: N
mild
assessed
2026-08-18
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 139); relationship: N
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-28 (study day 321); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-21 (study day 375); relationship: N
severe
serious
assessed
2026-08-18
Grade 4 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-05-10 (study day 577); relationship: Y; serious criteria: life-threatening
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-15 (study day 674); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.